• search
Viral Vectors Viral Vectors

Viral Vectors

We offer a diverse range of services in the area of viral vector generation for Cell and Gene Therapy (CGT).

The most effective method of gene transfer for modifying specific cell types or tissues is viral vector, which can be used for expressing therapeutic genes.

Speak to our experts

Lentiviral vector system to develop producer cell lines (for difficult-to-express proteins)

  • Lentiviral system is useful when other transient expression systems viz. Expi / TranslT pro/ PEI yield low or negligible expression of target protein.
  • 10 to 100-fold higher titer as compared to transient expression
  • High stability of clones/ pool without selection pressure
  • Rapid selection resulting in faster TAT (4 - 6 weeks)
  • Cost effective

Lentiviral vector system to develop Reporter cell lines (GFP / RFP/ F-luc expressing cell lines)

  • Reporter cell lines are tools for in vitro / in vivo screening and efficacy evaluation
  • These cell lines (RFP/F-Luc) enable non-invasive detection and quantitation of subcutaneous, orthotopic, and metastatic xenografts in preclinical mouse models using bioluminescent imaging
  • Experience in generating orthotopic reporter cell lines for breast, prostate, melanoma, glioblastoma, colorectal, lung, and B-cell malignancies
  • In-house modified lentiviral vector system to develop reporter cell lines
  • Timelines: 12 - 16 weeks

Lentiviral vector system for generating Knock-down (KD) cell lines (SiRNA/ShRNA)

Knock-down cell lines are tools for in vitro / in vivo screening, binding studies, and efficacy evaluation and serve as disease models:

  • Single, double, or multiple gene knock-down of primary and established cell lines
  • Timelines: 12 - 16 weeks

Why Aurigene Viral Vectors Services?

Customized vector construction

State-of-the-art facilities

Regulatory audits and compliance to statutory norms

Team of scientists with extensive experience in viral vector generation

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Resources

PROTACs: Research for a life without cancer

OCTOBER 01, 2024

PROTACs: Research for a life without cancer

PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...

Read More
View All

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...

Read More
View All

Cell Line Development

We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...

Read More
View All

Case study: Tackling CYP 2C9 inhibition challenges

The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...

Read More
View All

Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry

2022

Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack

X

Leaving already?

Don't forget to join us at

CPHI Worldwide 2023.

October 24th-26th, 2023 | Barcelona, Spain

Get ready to accelerate your drug’s journey to the market